These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

729 related items for PubMed ID: 15561813

  • 41. Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Herrington JD, Davidson SL, Tomita DK, Green L, Smith RE, Boccia RV.
    Am J Health Syst Pharm; 2005 Jan 01; 62(1):54-62. PubMed ID: 15658073
    [Abstract] [Full Text] [Related]

  • 42. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
    Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC, Tezcan H, Waples J, Ward J, Yee LK.
    Cancer; 2004 Feb 15; 100(4):859-68. PubMed ID: 14770445
    [Abstract] [Full Text] [Related]

  • 43. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA, Harpe SH, Brophy GM.
    Pharmacotherapy; 2007 Apr 15; 27(4):535-41. PubMed ID: 17381380
    [Abstract] [Full Text] [Related]

  • 44. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
    Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C.
    Curr Med Res Opin; 2005 Oct 15; 21(10):1677-82. PubMed ID: 16238908
    [Abstract] [Full Text] [Related]

  • 45. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA, Walker R, Australian Renal Anaemia Group.
    Nephrology (Carlton); 2007 Apr 15; 12(2):126-9. PubMed ID: 17371333
    [Abstract] [Full Text] [Related]

  • 46. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
    Ariganello O, Mancuso A, Di Molfetta M, Diana F, Beccaglia P, Cortesi E, De Marinis F.
    Lung Cancer; 2004 Oct 15; 46(1):119-24. PubMed ID: 15364140
    [Abstract] [Full Text] [Related]

  • 47. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.
    Nefrologia; 2003 Oct 15; 23(2):114-24. PubMed ID: 12778875
    [Abstract] [Full Text] [Related]

  • 48. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
    Patton JF, Sullivan T, Mun Y, Reeves T, Rossi G, Wallace JF.
    J Support Oncol; 2005 Oct 15; 3(6):419-26. PubMed ID: 16350429
    [Abstract] [Full Text] [Related]

  • 49. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S, Boulton H, Gokal R.
    J Nephrol; 2004 Oct 15; 17(5):687-92. PubMed ID: 15593036
    [Abstract] [Full Text] [Related]

  • 50. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy.
    Crawford J, Robert F, Perry MC, Belani C, Williams D, Anemia Prevention in NSCLC Group.
    J Thorac Oncol; 2007 Mar 15; 2(3):210-20. PubMed ID: 17410044
    [Abstract] [Full Text] [Related]

  • 51. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
    Horowitz J, Agarwal A, Huang F, Gitlin M, Gandra SR, Cangialose CB.
    J Manag Care Pharm; 2009 Mar 15; 15(9):741-50. PubMed ID: 19954265
    [Abstract] [Full Text] [Related]

  • 52. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O, Garassino M, Sacchetta S, Caristo R, Zivi A, Cerbone L, Mancuso A.
    Anticancer Res; 2008 Mar 15; 28(3B):1767-71. PubMed ID: 18630457
    [Abstract] [Full Text] [Related]

  • 53. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M, Thimons DG, Winston JL, Langholff W, McGowan T.
    J Am Med Dir Assoc; 2012 Mar 15; 13(3):244-8. PubMed ID: 21450214
    [Abstract] [Full Text] [Related]

  • 54. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.
    Abdelrazik N, Fouda M.
    Hematology; 2007 Dec 15; 12(6):533-41. PubMed ID: 17852440
    [Abstract] [Full Text] [Related]

  • 55. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks.
    Vadhan-Raj S, Mirtsching B, Charu V, Terry D, Rossi G, Tomita D, McGuire WP.
    J Support Oncol; 2003 Dec 15; 1(2):131-8. PubMed ID: 15352656
    [Abstract] [Full Text] [Related]

  • 56. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
    Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C.
    Nephrol Dial Transplant; 2006 Oct 15; 21(10):2846-50. PubMed ID: 16891642
    [Abstract] [Full Text] [Related]

  • 57. Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.
    Vansteenkiste JF.
    Cancer Treat Rev; 2006 Oct 15; 32 Suppl 2():S11-5. PubMed ID: 16725268
    [Abstract] [Full Text] [Related]

  • 58. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
    van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P.
    Eur Heart J; 2007 Sep 15; 28(18):2208-16. PubMed ID: 17681958
    [Abstract] [Full Text] [Related]

  • 59. Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naïve patients and patients switched from epoetin alfa.
    Thames WA, Smith SL, Scheifele AC, Yao B, Giffin SA, Alley JL.
    Pharmacotherapy; 2004 Mar 15; 24(3):313-23. PubMed ID: 15040644
    [Abstract] [Full Text] [Related]

  • 60. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
    Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF.
    J Clin Oncol; 2005 Apr 20; 23(12):2606-17. PubMed ID: 15452187
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.